Similar articles

• ADT in prostate cancer and risk of Alzheimer's disease.

  Bagcchi S. Bagcchi S. Lancet Oncol. 2016 Jan;17(1):e12. doi: 10.1016/S1470-2045(15)00578-1. Epub 2015 Dec 11. Lancet Oncol. 2016. PMID: 26687595 No abstract available.
• Prostate cancer: Increased dementia risk following androgen deprivation therapy?

  Martins RN, Gandy S. Martins RN, et al. Nat Rev Urol. 2016 Apr;13(4):188-9. doi: 10.1038/nrurol.2016.34. Epub 2016 Feb 23. Nat Rev Urol. 2016. PMID: 26902342 No abstract available.
• Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

  Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, Shah NH. Nead KT, et al. J Clin Oncol. 2016 Feb 20;34(6):566-71. doi: 10.1200/JCO.2015.63.6266. Epub 2015 Dec 7. J Clin Oncol. 2016. PMID: 26644522 Free PMC article.
• Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.

  Gomella LG. Gomella LG. BJU Int. 2007 Jan;99 Suppl 1:1. doi: 10.1111/j.1464-410X.2007.06590.x. BJU Int. 2007. PMID: 17229158 Review. No abstract available.
• Role of radiation and androgen deprivation therapy for advanced prostate cancer.

  Jani AB, Rossi PJ. Jani AB, et al. Curr Probl Cancer. 2015 Jan-Feb;39(1):41-7. doi: 10.1016/j.currproblcancer.2014.11.007. Epub 2014 Nov 25. Curr Probl Cancer. 2015. PMID: 25554467 Review. No abstract available.